Clinical Trial Results: ocrelizumab

Product Name: ocrelizumab
Date of Report: To be Published
Phase: II
A Study of Ocrelizumab in Patients with Rheumatoid Arthritis

Product Name: ocrelizumab
Date of Report: To be Published
Phase: II
A Study of Ocrelizumab in Patients with Follicular Non-Hodgkin’s Lymphoma (NHL)

Product Name: ocrelizumab
Date of Report: To be Published
Phase: III
A Study of Ocrelizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate.

Product Name: ocrelizumab
Date of Report: To be Published
Phase: III
A Study of Ocrelizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to anti-TNF-alpha Therapy.

Product Name: ocrelizumab
Date of Report: To be Published
Phase: III
A Study of Ocrelizumab in Combination With Methotrexate in Patients with Rheumatoid Arthritis Who Are Naive to Methotrexate.

Product Name: ocrelizumab
Date of Report: To be Published
Phase: III
A Study of Ocrelizumab in Patients With Systemic Lupus Erythematosus.

Product Name: ocrelizumab
Date of Report: To be Published
Phase: III
A Study of Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus.

Product Name: ocrelizumab
Date of Report: To be Published
Phase: III
A Study of Ocrelizumab Given as a Single or Dual Infusion in Patients With Rheumatoid Arthritis Who Have An Inadequate Response to Methotrexate

Product Name: ocrelizumab
Date of Report: To be Published
Phase: II
A Dose-Finding Study of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis.